




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Rater Agreement: Mean vs. STD



30 EMF COVID-19 Infection Experiences and Social Determinants of Health in North Carolina: A Qualitative Analysis



Purakal JD, Seidenfeld J, Tupetz A, Vissoci J, Silva L, Limkakeng A, Fiorino C, Phillips A, Staton C/Duke University School of Medicine, Durham, North Carolina, Duke University School of Medicine, Duke University School of Medicine, Duke University School of Medicine, Universidad de Maringá, Duke University School of Medicine, Duke University School of Medicine, Duke University Hospital, Duke University School of Medicine

Study Objectives: Social determinants of health (SDOH) influence the health outcomes of COVID-19 patients; yet, little is known about how patients at risk of significant disease burden view this relationship. Our study sought to explore patient perceptions of the influence of SDOH on their COVID-19 infection experience and COVID-19 transmission within their communities.

Methods: We conducted a qualitative study of patients in a North Carolina health care system’s registry who tested positive for COVID-19 from March 2020 through February 2021. All patients’ addresses across six counties served were geo-referenced and analyzed by Kernel Density Estimation (KDE) to identify population-dense outbreaks of COVID-19 (hotspots). Spatial autocorrelation analysis was performed to identify census area clusters of white, Black and Hispanic populations, based on the 2019 American Community Survey dataset. Patients were identified by a randomized computer-generated sampling method. Patients participated in semi-structured phone interviews in English or Spanish based on patient preference by trained bilingual researchers. Each interview was evaluated using a combination of deductive and inductive content analysis to determine prevalent themes related to COVID-19 knowledge and diagnosis, disease experience, and the impact of SDOH.

Results: The 10 patients interviewed from our COVID-19 hotspots were of equal distribution by sex, and predominantly Black (70%), ages 22-70 years (IQR 45-62 years), and presented to the ED for evaluation (70%). The respondents were more frequently publicly insured (50% medicaid/medicare; vs 30% uninsured; vs 20% private). The interviews demonstrated themes surrounding the experience and impact of COVID-19. The perceived risk of contracting COVID-19 and knowledge of how to prevent infection varied greatly and could be in part explained by SDOH such as their occupation and living conditions. The experiences of COVID-19 testing, diagnosis, isolation and treatment were most influenced by the timing of infection in relation to the study period. Earlier in the pandemic, the knowledge of isolation requirements and available support systems seemed to have negatively impacted the ability to isolate and follow public health guidance, as well as the support mechanisms provided by employers during this period. Communication of infection status once diagnosed varied greatly, with some voicing feelings of shame, and others advocating for sharing of infection experiences to change community behaviors. Suggestions for how to improve the COVID-19 response included

improving communication and enforcing public health guidelines, including raising awareness for vulnerable populations.

Conclusion: Further exploration of important themes and related SDOH that influenced how the participants experienced the COVID-19 pandemic will be necessary to decrease the negative impacts of SDOH in communities that are high-risk for COVID-19 spread.

31 Emergency Department-Based Monoclonal Antibody Therapy for Patients With Mild to Moderate COVID-19



Lim C, Eiting E, O’Neill A, Farraj R, Koshy S, Simms C, Devlin A, Nunez J, Calderon Y /Mount Sinai Health System, New York, New York, Icahn School of Medicine at Mount Sinai, New York, New York, Mount Sinai Beth Israel, New York Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, New York, New York, Mount Sinai Beth Israel, New York, New York, Icahn School of Medicine at Mount Sinai, New York, New York, Icahn School of Medicine at Mount Sinai, New York, New York, Icahn School of Medicine at Mount Sinai, New York, New York

Study Objective: Monoclonal antibody therapy (MOAB) has recently emerged as a treatment for mild to moderate COVID-19, potentially preventing those with underlying conditions from progressing to severe illness and hospitalization. While MOAB administration has commonly been restricted to infusion centers or inpatient settings, the infection prevention needs of patients with acute COVID-19 and the ambulatory nature of the therapy make the emergency department (ED) a useful setting to offer this treatment. Further, as EDs are the primary point of health care access for many at-risk individuals, offering MOAB in the ED may increase availability of treatment options for patients from traditionally underserved communities.

Methods: A retrospective chart review was conducted of patients 12 years and above who received treatment in our urban, academic, community hospital. A multidisciplinary group comprised of stakeholders in emergency medicine, pediatrics, infectious disease, nursing, informatics, and pharmacy developed a comprehensive ED-based MOAB program. Patients 12 years and older were screened for eligibility during ED visits or during follow-up calls providing positive test results. Staff was trained on specific consent, infusion, monitoring, and documentation procedures adherent to MOAB administration under the Emergency Use Authorization. Patients were contacted following MOAB and queried regarding symptom resolution and health care utilization. Data regarding patient demographics, ED course, and 7-day unscheduled visits were collected.

Results: In this ongoing quality improvement initiative, from December 2020 to March 2021, there were 26,229 patient encounters at the pilot ED site. 84 patients were provided MOAB, 87% Bamlanivimab and 13% Bamlanivimab/Etesevimab. Patients had a mean age of 52.3 years (SD 24.4); 21% were 12-17 years of age and 37% were >65 years old. 52% were male. 33% self-reported as Caucasian, 19% Black, 18% Asian/Pacific Islander, 21% as other, and 9% were unknown. 17% identified as Latinx. 19% of patients were insured by Medicaid, 36% Medicare, 39% commercially insured, and 6% were uninsured. Patients had symptoms a median of 3 days prior to MOAB. After age (46%), the most commonly reported eligibility criteria was obesity (20%), followed by hypertension (11%) and immunocompromised state (11%). 74% of infusions were administered during nights and weekends. No infusion reactions occurred. 8% returned to an ED within 7 days of MOAB, 5% were hospitalized. No patients required ICU admission or died.

Conclusion: ED-based MOAB has been safely implemented and may be an effective treatment for patients with mild to moderate COVID-19. Health-system-wide expansion of this program may provide opportunities to offer this life-saving therapy to underserved populations with poor access to care.

32 Decay of Anti-SARS-CoV-2 Nucleocapsid IgG in Seropositive Health Care Workers Over Time



Tiffany B, Cogo J, Bremner R, Zumbuhl J, Wood L, Sanders S, The CONSERVE-HCW Research Group/Dignity Health Research Institute Arizona/ Dignity Health Arizona General Hospital, Mesa, Arizona, Dignity Health St. Joseph’s Hospital and Medical Center/Barrows Neurologic Institute, Dignity Health St. Joseph’s Hospital and Medical Center/Norton Thoracic Institute, Dignity Health Research Institute–East Valley, Dignity Health St. Joseph’s Hospital and Medical Center, Dignity Health Research Institute Arizona/College of Nursing and Health Innovation, Arizona State University

Study Objectives: Our understanding of the quality and duration of immunity to COVID-19 following natural infection remains important area of public health research. The long-term kinetics of IgG antibodies to the spike and